Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1989;74:371-374
© 1989 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ROSA, F. W.
Right arrow Articles by CREAMER, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ROSA, F. W.
Right arrow Articles by CREAMER, J.

Neonatal Anuria With Maternal Angiotensin- Converting Enzyme Inhibition

FRANZ W. ROSA, MD, MPH, LYNN A. BOSCO, MD, MPH, CHERYL FOSSUM GRAHAM, MD, JULIE B. MILSTIEN, PhD, MICHAEL DREIS, RPh, MPH and JOYCE CREAMER, BSN, MBA

From the Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland

Abstract

The use of angiotensin-converting enzyme inhibitors as antihypertensives has increased rapidly since the introduction of captopril in 1981. Seven cases of neonatal renal failure have been reported in patients with exposure to angiotensin-converting enzyme inhibitors that continued to the time of delivery. Two cases resulted in death of the newborn; the other five patients recovered after peritoneal dialysis. Because the relative frequency of normal outcomes is unknown, these data are insufficient for incidence-rate estimates or risk/benefit analyses. However, given the potential neonatal morbidity and mortality associated with late-pregnancy exposure to angiotensin-converting enzyme inhibitors, alternative therapies in the third trimester should be given consideration. If these drugs must be used in this context, the clinician should be prepared to deal with renal failure and hypotension in the newborn. The Food and Drug Administration invites reports of adverse pregnancy outcomes associated with such exposure




This article has been cited by other articles:


Home page
 Arch Intern MedHome page
D. K. Wysowski and L. Swartz
Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002: The Importance of Reporting Suspected Reactions
Arch Intern Med, June 27, 2005; 165(12): 1363 - 1369.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
G Filler, H Wong, A S Condello, C Charbonneau, B Sinclair, T Kovesi, and J Hutchison
Early dialysis in a neonate with intrauterine lisinopril exposure
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2003; 88(2): F154 - F156.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
T. R. EASTERLING, D. B. CARR, C. DAVIS, C. DIEDERICHS, D. A. BRATENG, and B. SCHMUCKER
Low-Dose, Short-Acting, Angiotensin-Converting Enzyme Inhibitors as Rescue Therapy in Pregnancy
Obstet. Gynecol., December 1, 2000; 96(6): 956 - 961.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Koren, A. Pastuszak, and S. Ito
Drugs in Pregnancy
N. Engl. J. Med., April 16, 1998; 338(16): 1128 - 1137.
[Full Text] [PDF]

Home page
 NEJMHome page
B. M. Sibai
Treatment of Hypertension in Pregnant Women
N. Engl. J. Med., July 25, 1996; 335(4): 257 - 265.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American College of Obstetricians and Gynecologists.